Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2013

01-10-2013 | Letter to the Editor

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation

Authors: Massimo Breccia, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena

Published in: Annals of Hematology | Issue 10/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, International Vidaza High-Risk MDS Survival Study Group et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232PubMedCrossRef
2.
Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndrome. J Clin Oncol 29:516–523PubMedCrossRef
3.
Keating GM (2012) Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukemia. Drugs 72:1111–1136PubMedCrossRef
4.
Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellstrom-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218–227PubMedCrossRef
5.
Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G (2012) 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 53(8):1558–1560PubMedCrossRef
6.
Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F et al (2010) 5-Azacitidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45:872–876PubMedCrossRef
7.
Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R, Finke J (2010) Efficacy of a 3-day, low-dose treatment with 5-azacitidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627–632PubMedCrossRef
8.
Ustun C, Kalla A, Farrow S, DeRemer DL, Jilella A (2008) Decitabine as “bridge therapy” to a MUD transplant in relapsed AML postautologous stem cell transplantation. Am J Hematol 83:825–827PubMedCrossRef
Metadata
Title
Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation
Authors
Massimo Breccia
Adriano Salaroli
Alessandra Serrao
Giuliana Alimena
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1732-2

Other articles of this Issue 10/2013

Annals of Hematology 10/2013 Go to the issue

Letter to the Editor

Acute vesiculobullous hand dermatitis and anagen effluvium in Ganoderma lucidum-induced aplastic crisis

Letter to the Editor

Optic neuritis preceding progressive outer retinal necrosis in an immunocompromised patient after allogeneic stem cell transplantation

Letter to the Editor

Necrotic and ulcerated cutaneous and mucosal leukemia cutis in AML6

Original Article

Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Original Article

De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”

Original Article

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits